New products with a huge commercial potential for CKD treatment and renal lithiasis.
AVEROA’s pipeline is composed of products targeting renal diseases.
Our lead product, AVA1014, is already registered in major kidney disease markets, including the US, Japan and South Korea, and should be registered by Averoa in Europe.
With the LUCIOL project, Averoa is working on a breakthrough treatment (AVA2206) with a new mechanism of action for Renal Lithiasis associated with a companion test (AVA2065).
By identifying and in-licensing late-stage drugs that have a strong therapeutic and commercial fit with our current portfolio.
By signing development agreement to develop our product outside EU territories.
By developing a network of commercial partners and distributors to maximize the potential of our registered products.
submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease.
